Stimulants in 2026: Meth, Cocaine, and the Prescription Shadow
The fourth wave of the crisis is stimulant-driven. And there's still no FDA-approved medication for stimulant use disorder.
Body — 8 lenses: [Science: monoamine release/reuptake (DA, NE, serotonin) — cocaine blocks; meth releases. Biology: hyperthermia, cardiac strain, neurotoxicity (dopamine terminals with chronic high-dose meth), dental effects (“meth mouth” from dry-mouth + acidic diet, not the drug directly). Psychology: the “euphoria gap” after the acute phase, stimulant psychosis in heavy meth use, ADHD/stimulant diagnosis intersection. Policy: Schedule II (meth, cocaine, Rx stimulants); DEA production quotas; Adderall shortage backstory. Trends: stimulant-involved deaths hit 57,500 in 2022, ~70% co-involving fentanyl — the fourth wave. Social: the crack-era racialized policy legacy and current disparities. Treatment: NO FDA-approved medication for stimulant UD; contingency management has the strongest evidence (RCTs 2–4× retention); CBT, community reinforcement, matrix model. Harm reduction: sleep, hydration, avoiding mixing with depressants, safer-use supplies, drug checking.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Doctors Are Writing Fewer Benzodiazepine Prescriptions. The Counterfeits Are Getting Stronger.
Benzodiazepine dispensing fell 26.7% from 2013 to 2024 while designer benzodiazepines took over lab detections. What a pharmacist's twenty-year dependence, and his withdrawal, say about what is missing in between.
Science & MedicineThree Hundred and Seventy-One Trials Later, There Is Still No Approved Drug for Meth or Cocaine. The Best Treatment We Have Is a Gift Card.
An umbrella review of 371 trials found no approved medication for stimulant use disorder. What that means for people using meth or cocaine, and for the programs that serve them.
Science & MedicineOne Dose Quieted Her Head for Two Hours. Within Weeks She Was Buying More.
A 2026 BJPsych Open case report describes a 25-year-old woman who developed ketamine addiction after one clinical dose. What it shows about relief, dependence and what clinics and clients should ask.